QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
TLV update: What actually changes as of 1 October for market access in Sweden
TLV has published new general guidelines and version 7.0 of its handbook for pharmaceutical reimbursement and pricing applications. TLV’s new general guidelines and application regulations apply from 1 October 2026. For market access teams, this is not a methodological reset. TLV is mainly consolidating existing assessment practice into one framework. Comparator choice, severity assessment and health economic evaluation are described more explicitly but largely reflect current practice.
The practical changes […]
📢Publication alert!
We are pleased to share that our new publication, developed in partnership with the IFPA International Federation of Psoriasis Associations, ” Economic Impact of Timely Systemic Treatment of Psoriatic Disease in Comorbidity Risk Reduction”, has been published in Dermatology and Therapy.
Psoriasis and psoriatic arthritis are associated with an increased risk of serious comorbidities, including cardiovascular disease, type 2 diabetes, obesity, depression, and anxiety. […]
First JCA report published. What it means for Nordic HTA?
The first Joint Clinical Assessment report under the EU HTA Regulation is now published. It covers Ojemada® / tovorafenib, for paediatric low-grade glioma.
Across the Nordics, the message from national HTA agencies is consistent:
Do not resubmit clinical evidence already available through the JCA process.
Instead, use the JCA report and, where relevant, the JCA dossier as reference points in the national submission.
This is already reflected in national guidance:
📍 Denmark asks applicants […]
EHA 2026: Hematology innovation is advancing. Is your evidence strategy keeping pace?
Cathrine Tipsmark and Kelsi Smith will be attending EHA 2026 in Stockholm from 11–14 June (Thursday to Sunday).
They will be meeting with leaders across Medical Affairs, Market Access, HEOR, Clinical Development, and Commercial teams to discuss:
📊 Real-world evidence (RWE)
📊 External control arms and comparator studies
📊 EU HTA requirements, including JCA and JSC
📊 Cross-functional evidence planning to support successful launches
📊 Medical Affairs evidence generation and scientific communication
As part of the […]
